Latest Insider Transactions at Natera, Inc. (NTRA)
This section provides a real-time view of insider transactions for Natera, Inc. (NTRA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Natera, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Natera, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 05
2025
|
Rowan E Chapman |
SELL
Open market or private sale
|
Direct |
4,366
-22.7%
|
$1,060,938
$243.24 P/Share
|
|
Dec 05
2025
|
Rowan E Chapman |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+28.28%
|
$128,000
$32.15 P/Share
|
|
Dec 04
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,902
+3.2%
|
$131,138
$19.68 P/Share
|
|
Dec 01
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
4,400
-1.02%
|
$1,047,200
$238.21 P/Share
|
|
Dec 01
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
3,000
-0.68%
|
$714,000
$238.19 P/Share
|
|
Nov 24
2025
|
Roelof Botha Director |
SELL
Open market or private sale
|
Indirect |
75,000
-0.57%
|
$17,550,000
$234.43 P/Share
|
|
Nov 21
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
4,000
-7.91%
|
$920,000
$230.01 P/Share
|
|
Nov 20
2025
|
Roy D. Baynes |
SELL
Open market or private sale
|
Direct |
7,668
-6.72%
|
$1,702,296
$222.73 P/Share
|
|
Nov 20
2025
|
Roy D. Baynes |
BUY
Exercise of conversion of derivative security
|
Direct |
7,668
+12.21%
|
$314,388
$41.06 P/Share
|
|
Nov 20
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
10,000
-4.3%
|
$2,250,000
$225.08 P/Share
|
|
Nov 19
2025
|
Roy D. Baynes |
SELL
Open market or private sale
|
Direct |
5,112
-7.84%
|
$1,093,968
$214.78 P/Share
|
|
Nov 19
2025
|
Roy D. Baynes |
BUY
Exercise of conversion of derivative security
|
Direct |
5,112
+17.88%
|
$204,480
$40.93 P/Share
|
|
Nov 11
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
1,500
-0.97%
|
$312,000
$208.03 P/Share
|
|
Nov 07
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
3,070
-0.19%
|
$595,580
$194.12 P/Share
|
|
Nov 04
2025
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Direct |
22,900
-0.5%
|
$4,580,000
$200.73 P/Share
|
|
Nov 03
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
3,000
-0.88%
|
$594,000
$198.96 P/Share
|
|
Nov 03
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
4,000
-7.13%
|
$800,000
$200.07 P/Share
|
|
Nov 03
2025
|
Gail Boxer Marcus |
SELL
Open market or private sale
|
Direct |
122
-2.07%
|
$24,156
$198.71 P/Share
|
|
Nov 03
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
160,703
-17.77%
|
$31,819,194
$199.0 P/Share
|
|
Nov 03
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
155,679
+12.18%
|
$7,939,629
$51.01 P/Share
|
|
Nov 03
2025
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Direct |
17,100
-0.74%
|
$3,420,000
$200.0 P/Share
|
|
Oct 31
2025
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
93
+0.5%
|
-
|
|
Oct 31
2025
|
Monica Bertagnolli |
BUY
Grant, award, or other acquisition
|
Direct |
93
+1.75%
|
-
|
|
Oct 31
2025
|
Roelof Botha Director |
BUY
Grant, award, or other acquisition
|
Direct |
149
+2.13%
|
-
|
|
Oct 31
2025
|
Rowan E Chapman |
BUY
Grant, award, or other acquisition
|
Direct |
128
+2.04%
|
-
|
|
Oct 31
2025
|
Gail Boxer Marcus |
BUY
Grant, award, or other acquisition
|
Direct |
121
+2.02%
|
-
|
|
Oct 31
2025
|
Brinkley Ruth Williams |
BUY
Grant, award, or other acquisition
|
Direct |
97
+1.79%
|
-
|
|
Oct 29
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,867
-0.71%
|
$354,730
$190.35 P/Share
|
|
Oct 28
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,415
-0.89%
|
$461,265
$191.26 P/Share
|
|
Oct 28
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
3,680
-2.4%
|
$702,880
$191.46 P/Share
|
|
Oct 28
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
928
-0.61%
|
$177,248
$191.46 P/Share
|
|
Oct 28
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
1,198
-1.03%
|
$228,818
$191.46 P/Share
|
|
Oct 28
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,058
-0.52%
|
$202,078
$191.46 P/Share
|
|
Oct 28
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
191
-0.08%
|
$36,481
$191.46 P/Share
|
|
Oct 27
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
781
-1.13%
|
$149,952
$192.32 P/Share
|
|
Oct 27
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
2,335
-1.5%
|
$448,320
$192.32 P/Share
|
|
Oct 27
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
781
-0.51%
|
$149,952
$192.32 P/Share
|
|
Oct 27
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
1,008
-0.86%
|
$193,536
$192.32 P/Share
|
|
Oct 27
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
935
-0.46%
|
$179,520
$192.32 P/Share
|
|
Oct 27
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
288
-0.12%
|
$55,296
$192.32 P/Share
|
|
Oct 24
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
755
-1.08%
|
$147,980
$196.77 P/Share
|
|
Oct 23
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
495
-0.7%
|
$92,565
$187.16 P/Share
|
|
Oct 22
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+1.74%
|
-
|
|
Oct 22
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
920
-1.31%
|
$171,120
$186.68 P/Share
|
|
Oct 21
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
602
-0.85%
|
$112,574
$187.95 P/Share
|
|
Oct 21
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
1,603
-1.02%
|
$299,761
$187.95 P/Share
|
|
Oct 21
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
339
-0.22%
|
$63,393
$187.95 P/Share
|
|
Oct 21
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
292
-0.25%
|
$54,604
$187.95 P/Share
|
|
Oct 21
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
464
-0.23%
|
$86,768
$187.95 P/Share
|
|
Oct 21
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
93
-0.04%
|
$17,391
$187.95 P/Share
|